karthik Bommannan

Dr. karthik Bommannan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
KBkarthik Bommannan
karthik Bommannan
JAJhansi Rani Arumugam
Jhansi Rani Arumugam
SSShirley Sundersingh
Shirley Sundersingh
PRPriya T. Rajan
Priya T. Rajan
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
TSTenali Gnana Sagar
Tenali Gnana Sagar
Flow cytometric diagnosis and minimal residual disease (MRD) assessment of precursor B-lineage acute lymphoblastic leukemia (B-ALL) are heavily dependent on CD19 based gating strategies. However, this approach is not optimal in the diagnosis and follow-up of CD19 negative or dim B-ALLs. Though CD19 negative B-ALLs are rare, in the current era of CD19 targeted immuno-therapy, CD19 negative B-ALL relapses are frequent. We have presented our cohort of 14 de novo CD19 negative and dim B-ALLs and have highlighted the difficulties faced during diagnosis and MRD assessment of these patients. We have also discussed the need to identify alternative B-lineage gating markers and strategies to deal with such scenarios.

13 October 2016 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
KBkarthik Bommannan
karthik Bommannan
BGBalan Louis Gaspar
Balan Louis Gaspar
MSMan Updesh Singh Sachdeva
Man Updesh Singh Sachdeva
Sarcinais a Gram-positive anaerobic coccus that has been consistently reported in the upper gastrointestinal tract biopsies of patients with evidence of gastric stasis. The pathogenic role ofSarcinain humans is not entirely known. We describe an infant who was surgically treated for posterior urethral valve and the urine showed pathogenicSarcina.

5 March 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
KBkarthik Bommannan
karthik Bommannan
JAJhansi Rani Arumugam
Jhansi Rani Arumugam
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
SSShirley Sundersingh
Shirley Sundersingh

3 April 2023 in Indian Journal of Cancer
Verified
Journal Article
Open access
KJKavita Jain
Kavita Jain
KBkarthik Bommannan
karthik Bommannan
PGPrasanth Ganesan
Prasanth Ganesan
JAJhansi Rani Arumugam
Jhansi Rani Arumugam
TSTenali Gnana Sagar
Tenali Gnana Sagar
SSShirley Sundersingh
Shirley Sundersingh
Background: Multiple myeloma (MM) results from clonal expansion of immunoglobulin secreting, heavy chain class-switched, terminally differentiated B-lymphocytes (plasma cells), resulting in radiologic or biochemical evidence of end-organ damage. Though neurological manifestations (peripheral neuropathies, spinal radiculopathies, cranial nerve palsies, and metabolic encephalopathies) can occur during the disease course, direct central nervous system (CNS) infiltration by malignant plasma cells (CNS-MM) is very rare (~1%) and has a dismal prognosis (survival of <6 months). Methodology: Clinico-laboratory profile and outcome of CNS-MM patients diagnosed and treated at a tertiary cancer care hospital were retrospectively analyzed. Results: On scrutinizing 500 consecutive myeloma case records, 4 patients with CNS-MM were identified. All these patients were diagnosed during myeloma relapse, and all had deceased within 1 week and 12 months of developing CNS infiltration. Our experience with CNS-MM patients is similar to the experiences documented across major world literature. Conclusion: Our manuscript reinforces that CNS-MM should be considered in any myeloma patient presenting with unexplainable CNS manifestations. As there are no prospective studies to recommend optimal treatment strategies, CNS-MM still remains a dismal complication of myeloma.

2 November 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JAJhansi Rani Arumugam
Jhansi Rani Arumugam
KBkarthik Bommannan
karthik Bommannan
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
TSTenali Gnana Sagar
Tenali Gnana Sagar
SSShirley Sundersingh
Shirley Sundersingh
The major challenge in minimal residual disease (MRD) detection is the antigen modulation in post treated samples restraining the use of diagnostic immunophenotypic (IP) signature of leukemic blasts for MRD detection. The IP expression of 10 antigens in 167 children diagnosed as B-acute lymphoblastic leukemia (B-ALL) in comparison to hematogones and the extent of immunomodulation in 60 post treated MRD positive cases were studied. Upregulation was the predictable shift noted in antigens like CD73, CD86, CD19, CD20 and CD45 which was statistically significant for all except CD45. Downregulation was the predictable shift noted in antigens like CD10, CD38, CD58 and CD34 and was statistically significant in all. CD123 showed no significant trend. This immunomodulation in B-ALL results in aberrant expression of antigens during follow-up compared to the diagnostic phenotypic pattern. Hence it is necessary to be aware of the immunomodulations of antigens used in primary diagnosis to avoid being misled during MRD analysis.

20 December 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
KBkarthik Bommannan
karthik Bommannan
JAJhansi Rani Arumugam
Jhansi Rani Arumugam
TKTeena Koshy
Teena Koshy
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
TSTenali Gnana Sagar
Tenali Gnana Sagar
SSShirley Sundersingh
Shirley Sundersingh